2025 Autumn Conference – Includes Joint Day with ECNP
ECNP/ISCTM Joint Meeting Prior to 38th ECNP Congress 2025: CNS Clinical Trial Methodology
09 – 11 October, 2025 // Amsterdam, The Netherlands
Distinguished Poster Award Recipient:
|
|||
| Kolár – Using large language models for endpoint oversight (Abstract) | |||
|
View all Poster PDFs and Abstracts |
|||
10 October 2025 |
|||
| Welcome from the ISCTM and ECNP Presidents | Luca Pani Martien Kas  slides video |
||
| Session 1: From population to precision psychiatry: Promises, pitfalls, and paths forward | Chairs: Uma Vaidyanathan Andreas Reif |
||
| Introduction | Andreas Reif slides video |
||
| Biomarker discovery and development in neurological disorders – federated analyses as one potential solution | Bjoern Tackenberg* slides |
||
| Can EEG become the “ECG of neuropsychiatry”? | Ken Wang* slides |
||
| The role of digital health technologies (DHTs) in precision psychiatry approaches | Bill Simpson slides video |
||
| Promise, provisos & pitfalls of precision psychiatry approaches in drug development | Carla Canuso slides video |
||
| What does precision psychiatry mean, precisely? Sleep as an example | Thomas Pollmächer slides video |
||
| Precision psychiatry in the UK NHS – focus on depression | Anthony Cleare slides video |
||
| Precision psychiatry: A perspective on challenges and opportunities | Lorenzo Guizzaro slides video |
||
| From population to precision: Regulatory pathways for biomarker‑driven psychiatry trials | Luca Pani slides video |
||
| Panel discussion | Facilitator: Uma Vaidyanathan slides video |
||
|
Session 2: Current gaps regarding the approval of psychedelic compounds: Design of clinical trials and engagement with regulators |
Chairs: Walter Dunn Gitte Knudsen |
||
| Introduction – Current landscape of psychedelic drug development | Gitte Knudsen slides video |
||
| Psychedelic drugs in psychiatry – From clinical trials to post-approval considerations: A European regulatory perspective | Marion Haberkamp slides video |
||
| Restricted medical use of prohibited narcotics | Anna Rickli* slides |
||
| Regulatory panel discussion including US perspective | Facilitator: Walter Dunn Discussant: Valentina Mantua video |
||
| Knowledge gaps in psychedelic treatments and solutions through novel clinical designs | Amir Inamdar slides video |
||
| Beyond acute dosing: Safety concerns and adverse effects surrounding psychedelic treatments | Corine de Boer slides video |
||
| Managing expectation and bias in psychedelic clinical trials: Challenges and strategies | Guy Goodwin* video |
||
| The ISCTM working group on methodological issues in psychedelic clinical trials | Joyce Tsai slides video |
||
| Australian MDMA/psilocybin experience | Michael Winlo slides video |
||
| Panel discussion | Facilitator: Walter Dunn video |
||
|
Poster Session |
Poster PDFs and Abstracts | ||
11 October 2025 |
|||
| Session 3: Uncovering hidden lessons in CNS global clinical trials | Chairs: Dragana Bugarski-Kirola Dennis Hernaus |
||
| Introduction | Dragana Bugarski-Kirola slides video |
||
| Sharing the knowledge: Unpacking critical lessons from completed trials | Christoph von der Goltz* Corey Fowler* video |
||
| Assessing regional and temporal differences in multinational clinical trials | Alan Kott slides video |
||
| Considerations for risk-based data monitoring and eligibility review in depression global trials | Jenicka Engler slides video |
||
| Lessons which have not been learned in clinical trials in schizophrenia | Stefan Leucht* |
||
| Uncovering hidden lessons in CNS global clinical trials | Ricardo Marcelo Corral slides video |
||
| Success in today’s complex clinical trials: Perspectives from various site staff | Elan Cohen slides video |
||
| Conducting clinical trials in Serbia | Cedomir Miljevic slides video |
||
| Panel discussion including regulatory perspectives on recent challenges in global trials and how to address them | Discussants: Ni Khin slides videoLorenzo Guizzaro slidesAll Speakers video |
||
| Session adjourns | Luca Pani slides |
||
|
Concurrent Working Group Sessions |
|||
| Accelerating development of psychopathology measures – ISCTM/ECNP joint working group | Chairs: Nina Schooler Celso Arango Jenicka Engler slides |
||
| Defining and standardizing vocal biomarker outcomes working group | Chairs: Alex Cohen Jan Sedway slides |
||
| Orphan diseases working group | Chairs: Joan Busner Gahan Pandina slides summary |
||
| Sleep methodology in CNS trials working group | Chairs: Georg Dorffner Margaret Moline slides summary |
||
| *Slides and/or video not released | |||